190PDResearch-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. (23rd October 2018) - Bianchini, G; Parker, J; Carey, L; Perou, C M; Sica, L; Prat, A; Pieńkowski, T; Im, Y-H; Bianchi, G V; Ling-Ming, T; Liu, M-C; Lluch, A; et al.